p70S6K: A Protein Targeted for Tumor Treatment (P11291)

Target Name: Ribosomal Protein S6 Kinase, 70kDa (p70S6K)

NCBI ID: P11291

Ribosomal Protein S6 Kinase, 70kDa (p70S6K)

Other Name(s): p70S6K

p70S6K: A Protein Targeted for Tumor Treatment

Ribosomal Protein S6 Kinase (70kDa) (p70S6K) is a protein that plays a crucial role in the regulation of gene expression and cell signaling. It is a key enzyme in the S6K complex, which is responsible for phosphorylating histones and affecting their stability. In various cancers, abnormal activation or inhibition of p70S6K has become an important research target. At the same time, p70S6K is also considered a potential target for many drugs and has high pharmacological value.

First, we need to understand the structure and function of p70S6K. p70S6K is a 26kDa protein whose active center contains one serine residue and two phosphorylation sites. The phosphorylation site is where p70S6K binds to the substrate. Through phosphorylation, p70S6K can regulate the stability of histones and affect gene expression. In addition, p70S6K can also interact with other proteins, such as histone methyltransferases (HATs) and histone denaturants (DACs), thereby affecting the complex process of gene expression.

Next, we need to understand the role of p70S6K in tumors. Studies have shown that p70S6K is abnormally activated or inhibited in a variety of cancers, such as lung cancer, liver cancer, breast cancer, etc. Abnormally activated p70S6K can lead to abnormal gene expression and promote the growth and spread of tumor cells. Inhibiting p70S6K can significantly inhibit the growth and spread of tumor cells. Therefore, p70S6K has become an important target in tumor treatment.

At the same time, p70S6K is also considered as a potential target for many drugs. Many anti-tumor drugs, such as chemotherapy drugs, radiotherapy drugs, targeted drugs and immune drugs, can exert their anti-tumor effects by inhibiting the activity of p70S6K. For example, irinotecan is a topoisomerase inhibitor that blocks the topoisomerase-mediated changes in DNA topology by inhibiting the activity of p70S6K, thereby inhibiting the growth of tumor cells.

In addition, the expression level of p70S6K can also be used as a biomarker in tumor treatment. Some studies have shown that the expression level of p70S6K is closely related to tumor prognosis and treatment response. When the expression level of p70S6K is low, the survival period of tumor patients is shorter and the treatment effect is poor. Therefore, detecting the expression level of p70S6K can help doctors understand the effect of tumor treatment and provide patients with more effective treatment options.

In addition, some studies have also shown that the activity of p70S6K can be modulated by certain traditional Chinese medicines. For example, ginsenosides can significantly inhibit the activity of p70S6K, thereby inhibiting the growth of tumor cells. Therefore, ginsenosides can be used as a potential tumor treatment drug.

In summary, p70S6K is a protein with important value and potential in tumor treatment. By inhibiting the activity of p70S6K, the growth and spread of tumor cells can be significantly inhibited, providing more effective treatment options for tumor patients. At the same time, the expression level of p70S6K can also be used as a biomarker in tumor treatment, helping doctors understand the effect of tumor treatment. Therefore, p70S6K is a protein worthy of further study and has high pharmacological value.

Protein Name: Ribosomal Protein S6 Kinase, 70kDa (p70S6K) (nonspecified Subtype)

The "Ribosomal Protein S6 Kinase, 70kDa (p70S6K) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Ribosomal Protein S6 Kinase, 70kDa (p70S6K) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets